EGFR and non-small cell lung carcinoma: In non-small cell lung cancer, results from clinical trials have revealed that there were no survival benefits for EGFR-mutant non-small cell lung cancer (NSCLC) patients with the treatment of subsequent immunotherapy [53, 54].